7-Amino-3-(2'-deoxy-beta-D-ribofuranosyl)pyrazolo[4,3-d]
pyrimidine (2'-deoxyformycin A) was synthesized from
formycin A by a sequence consisting of (i) 3',5'-cyclosilylation with 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane, (ii) 2'-acylation with phenoxythiocarbonyl
chloride and 4-(N,N-dimethylamino)pyridine, (iii) N-trimethylsilylation with
hexamethyldisilazane, (iv) reduction of the 2'-O-phenoxythiocarbonyl group with
tri-n-butyltin hydride, and (v) desilylation with tetra-n-butylammonium
fluoride.
2'-Deoxyformycin A was a potent inhibitor of the in vitro growth of S49
lymphoma, a murine
tumor of T-cell origin. The IC50 of
2'-deoxyformycin A against S49 cells was 10-15 microM, whereas that of
2'-deoxyadenosine (dAdo) under the same conditions (72-h incubation in medium containing heat-inactivated horse serum) was 180 microM. In the presence of 10 microM erythro-9-(2-hydroxy-3-nonyl)adenine (
EHNA) to block intracellular
adenosine deaminase (ADA) activity,
2'-deoxyformycin A and dAdo both gave IC50's of 5-10 microM. When assayed against a mutant S49 subline lacking
adenosine kinase (AK) or a subline with a combined deletion of AK and
deoxycytidine kinase (dCK),
2'-deoxyformycin A in combination with 10 microM
EHNA was inactive at concentrations of up to 50 microM. Similar lack of activity against
kinase-deficient cells was shown by
formycin A. Thus, phosphorylation of
2'-deoxyformycin A appears to be required for
biological activity and is probably catalyzed by AK rather than dCK.
2'-Deoxyformycin A and related 2'-deoxyribo-C-nucleoside analogues of the
purine type may be of interest as potential T-cell specific
cytotoxic agents.